2-甲基吲哚-3-乙酸 | 1912-43-2

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 2-甲基吲哚-3-乙酸
• 中文别名: 2-甲基-3-吲哚乙酸
• 英文名称: 2-methyl-3-indoleacetic acid
• 英文别名: 2-methylindole-3-acetic acid；2-(2-methyl-1H-indol-3-yl)acetic acid；(2-methylindol-3-yl)acetic acid
• CAS: 1912-43-2
• 化学式: C₁₁H₁₁NO₂
• mdl: MFCD00075006
• 分子量: 189.214
• InChiKey: QJNNHJVSQUUHHE-UHFFFAOYSA-N

物化性质

• 熔点：
  205 °C (dec.) (lit.)
• 沸点：
  418.2±30.0 °C(Predicted)
• 密度：
  1.299±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）
• 稳定性/保质期：

  如果按照规定使用和储存，则不会分解，不存在已知的危险反应。应避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  53.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• WGK Germany：
  3
• 海关编码：
  2933990090
• 危险类别：
  IRRITANT
• 安全说明：
  S22,S24/25
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  请将贮藏器密封保存，在阴凉、干燥处储存，并确保工作环境有良好的通风或排气设施。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Methylindole-3-acetic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Methylindole-3-acetic acid
CAS number: 1912-43-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H11NO2
Molecular weight: 189.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

2-甲基吲哚-3-乙酸是一种常用的植物生长激素。

反应信息

• 作为反应物：
  描述：

  2-甲基吲哚-3-乙酸 在 lithium aluminium tetrahydride 、 2-碘酰基苯甲酸 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 18.58h， 生成 帕比司他
  参考文献：
  名称：

  [EN] PROCESS FOR THE PREPARATION OF PANOBINOSTAT
  [FR] PROCÉDÉ DE PRÉPARATION DE PANOBINOSTAT

  摘要：

  本发明涉及一种用于制备帕诺比诺斯他及其中间体的新工艺。

  公开号：

  WO2021170719A1
• 作为产物：
  描述：

  (2-methyl-indol-3-yl)-glyoxylic acid 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 18.0h， 生成 2-甲基吲哚-3-乙酸
  参考文献：
  名称：

  合成吲哚-3-乙酸的简便方法

  摘要：

  从相应的吲哚开始，通过吲哚-3-乙醛酸合成吲哚-3-乙酸，然后与对甲苯磺酰肼形成，然后用硼氢化钠还原hydr。

  DOI：

  10.1016/s0040-4039(00)76815-8

文献信息

• MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
  申请人：Combs Andrew Paul

  公开号：US20090286778A1

  公开（公告）日：2009-11-19

  The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及以下化学式I的大环化合物： 或其药用可接受盐或季铵盐，其中所述成员在此提供，并且它们的组成物和使用方法，这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用，例如炎症和自身免疫性疾病以及癌症。
• CHEMICAL SUBSTANCES WHICH INHIBIT THE ENZYMATIC ACTIVITY OF HUMAN KALLIKREIN-RELATED PEPTIDASE 6 (KLK6)
  申请人：Deutsches Krebsforschungszentrum

  公开号：EP3305781A1

  公开（公告）日：2018-04-11

  The invention relates to compounds which are suitable for the treatment of a disease associated with kallikrein-like peptidase 6 overexpression and to pharmaceutical compositions containing such compounds. The invention further relates to a kit of parts comprising such compounds or pharmaceutical compositions.

  这项发明涉及适用于治疗与kallikrein样肽酶6过度表达相关疾病的化合物，以及含有这些化合物的药物组合物。该发明还涉及包括这些化合物或药物组合物的配套工具包。
• Green Esterification of Carboxylic Acids Promoted by <i>tert</i> ‐Butyl Nitrite
  作者：Yonggao Zheng、Yanwei Zhao、Suyan Tao、Xingxing Li、Xionglve Cheng、Gangzhong Jiang、Xiaobing Wan

  DOI：10.1002/ejoc.202100326

  日期：2021.5.14

  TBN‐catalyzed green esterification of carboxylic acids has been developed, which features a broad range of substrates and excellent functional groups tolerance. The mechanistic study confirmed that the nitrous acid formed in situ in the system is the actual catalyst for this transformation.

  已经开发了TBN催化的羧酸绿色酯化反应，它具有多种底物和出色的官能团耐受性。机理研究证实，在系统中原位形成的亚硝酸是该转化的实际催化剂。
• Hypoglycemic imidazoline compounds
  申请人：ELI LILLY AND COMPANY

  公开号：EP1266897A3

  公开（公告）日：2003-12-03

  This invention relates to certain novel imidazoline compounds and analogues thereof, to their use for the treatment of diabetes, diabetic complications, metabolic disorders, or related diseases where impaired glucose disposal is present, to pharmaceutical compositions comprising them, and to processes for their preparation.The compounds have the following formula: whereinX is -O-, -S-, or -NR5-;R5 is hydrogen, C1-8 alkyl, or an amino protecting group;R4 isY is -O-, -S-, or -NR8-;Y' is -O- or -S-;

  本发明涉及某些新型的咪唑啉化合物及其类似物，以及它们用于治疗糖尿病、糖尿病并发症、代谢紊乱或相关疾病中的糖利用受损情况，涉及包含它们的药物组合物，以及它们的制备过程。这些化合物的公式如下：其中X是-O-，-S-，或-NR5-；R5是氢，C1-8烷基，或氨基保护基团；R4是Y是-O-，-S-，或-NR8-；Y'是-O-或-S-；
• Chemical profiling of HIV-1 capsid-targeting antiviral PF74
  作者：Lei Wang、Mary C. Casey、Sanjeev Kumar V. Vernekar、Ha T. Do、Rajkumar Lalji Sahani、Karen A. Kirby、Haijuan Du、Atsuko Hachiya、Huanchun Zhang、Philip R. Tedbury、Jiashu Xie、Stefan G. Sarafianos、Zhengqiang Wang

  DOI：10.1016/j.ejmech.2020.112427

  日期：2020.8

  herein the design, synthesis, and evaluation of a large number of PF74 analogs aiming to provide a comprehensive chemical profiling of PF74 and advance the understanding on its detailed binding mechanism and pharmacophore. The analogs, containing structural variations mainly in the aniline domain and/or the indole domain, were assayed for their effect on stability of CA hexamers, antiviral activity,

  HIV-1 的衣壳蛋白 (CA) 通过组装成功能性衣壳核心、控制脱壳和进入核的动力学以及与各种宿主因子相互作用，在病毒复制周期的多个步骤中发挥重要作用。靶向 CA 是一种有吸引力但尚未开发的抗病毒方法。在所有已知的靶向 CA 的小分子化学型中，拟肽 PF74 特别有趣，因为它与一些重要宿主因子使用的相同口袋结合，从而产生非常理想的抗病毒表型。然而，PF74 的进一步开发需要了解其药效团并减轻其较差的代谢稳定性。我们在此报告设计、合成、和评估大量 PF74 类似物，旨在提供 PF74 的全面化学分析，并促进对其详细结合机制和药效团的理解。分析了主要在苯胺结构域和/或吲哚结构域中包含结构变异的类似物对 CA 六聚体稳定性、抗病毒活性和细胞毒性的影响。还测试了选定的类似物在肝微粒体中的代谢稳定性，单独或在 CYP3A 抑制剂存在的情况下。总的来说，我们的研究确定了重要的药效团元素并揭示了 PF74

表征谱图